Literature DB >> 15351877

Proteins interacting with the tuberous sclerosis gene products.

M Rosner1, A Freilinger, M Hengstschläger.   

Abstract

Tuberous sclerosis (TSC) is an autosomal dominant tumor suppressor gene syndrome affecting about 1 in 6000 to 10000 individuals. The genes, TSC1, encoding hamartin, and TSC2, encoding tuberin are responsible for TSC. Since their identification 1997 and 1993 respectively, a variety of different functions have been described for the TSC gene products. Hamartin and tuberin form a complex, providing a tentative explanation for the similar disease phenotype in TSC patients with mutations in either of these genes. In addition, associations of hamartin or tuberin with several different proteins have been demonstrated. In this review, we summarize the current knowledge on hamartin- and tuberin-interacting proteins and discuss their role for the understanding of the functions of the TSC gene products.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351877     DOI: 10.1007/s00726-004-0119-z

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  8 in total

1.  Tuberin--a new molecular target in Alzheimer's disease?

Authors:  Rosa Ferrando-Miguel; Margit Rosner; Angelika Freilinger; Gert Lubec; Markus Hengstschläger
Journal:  Neurochem Res       Date:  2005-11       Impact factor: 3.996

2.  Lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Wendy K Steagall; Joel Moss
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2009

Review 3.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

4.  Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Authors:  Connie G Glasgow; Wendy K Steagall; Angelo Taveira-Dasilva; Gustavo Pacheco-Rodriguez; Xiong Cai; Souheil El-Chemaly; Marsha Moses; Thomas Darling; Joel Moss
Journal:  Respir Med       Date:  2010-07       Impact factor: 3.415

5.  Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.

Authors:  Anne Catharina Dressler; Gernot Hudelist; Anneliese Fink-Retter; Daphne Gschwantler-Kaulich; Georg Pfeiler; Margit Rosner; Markus Hengstschläger; Christian F Singer
Journal:  J Cancer Res Clin Oncol       Date:  2013-05-21       Impact factor: 4.553

Review 6.  Rapamycin and rapalogs for tuberous sclerosis complex.

Authors:  Teguh H Sasongko; Nur Farrah Dila Ismail; Zamh Zabidi-Hussin
Journal:  Cochrane Database Syst Rev       Date:  2016-07-13

7.  A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

Authors:  Gottfrid Sjödahl; Martin Lauss; Sigurdur Gudjonsson; Fredrik Liedberg; Christer Halldén; Gunilla Chebil; Wiking Månsson; Mattias Höglund; David Lindgren
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

8.  First comprehensive TSC1/TSC2 mutational analysis in Mexican patients with Tuberous Sclerosis Complex reveals numerous novel pathogenic variants.

Authors:  Miriam E Reyna-Fabián; Nancy L Hernández-Martínez; Miguel A Alcántara-Ortigoza; Jorge T Ayala-Sumuano; Sergio Enríquez-Flores; José A Velázquez-Aragón; Alfredo Varela-Echavarría; Carlos G Todd-Quiñones; Ariadna González-Del Angel
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.